Intensity begins Phase I/II of INT230-6 in advanced solid tumors

Intensity Therapeutics Inc. (Westport, Conn.) started the Phase I/II IT-01 trial to evaluate intratumoral INT230-6 with or without anti-PD-1 antibodies in about 60 patients with advanced solid tumors. Patients will receive injections every 14 or 28 days.

The open-label, U.S. and Canadian trial will evaluate safety as its primary endpoint and tumor response and pharmacokinetics as secondary endpoints...